Revolutionizing Immunotherapy: Ultra-Fast 30-Hour CAR T Cell Manufacturing with the SWIFT CAR T Platform for Next-Generation Autologous Therapy
Time: 2:45 pm
day: Conference Day One
Details:
- Ultra-Fast Manufacturing: The SWIFT CAR T platform reduces production time from 12–14 days to 30 hours, accelerating patient access to life-saving therapy.
- Superior T Cell Fitness: It preserves stemness, memory phenotypes, and enhances expansion, potency, and persistence, boosting antitumor efficacy.
- Efficiency & Accessibility: A cost-effective, low-toxicity, and adaptable approach that minimizes contamination risks, speeds up treatment, and sets a new immunotherapy benchmark with novel fully human CAR.
